Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Lancet Oncol. 2008 Oct 3;9(11):1039–1047. doi: 10.1016/S1470-2045(08)70235-3

Table 3.

Cox proportional hazard ratio (HR) a and 95% confidence interval (95% CI) of prostate cancer-specific mortality according to one unit increase in baseline BMI

HR (95% CI) P-value
All prostate cancer 1.09 (1.05–1.14) <0.0001
Controlling for aspirin and beta-carotene 1.09 (1.05–1.14) <0.0001
Excluding any deaths occurred first 5 years 1.10 (1.05–1.15) <0.0001
Excluding current smokers 1.11 (1.06–1.16) <0.0001
Excluding diabetes 1.09 (1.05–1.14) <0.0001
Excluding non-Caucasians 1.11 (1.05–1.16) <0.0001
Excluding stage T1 1.10 (1.05–1.15) <0.0001
Excluding metastasis (N1/M1) 1.08 (1.02–1.13) 0.0039
a

All adjusted for age at diagnosis, smoking status at baseline (past smoking for the analysis excluding current smokers) and time interval from baseline to prostate cancer diagnosis.